In support of this evidence, inactivating mutations of TRAF2 in MM patients cause the constitutive activation of the noncanonical NF-κB pathway, and TRAF2 expression is lower in IMiDs refractory-MM patients than in newly diagnosed patients still responsive to these drugs. Here, TRAF2 is linked to Miyoshi myopathy.